title: Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.
abstract: This study characterizes the relaxant response to 5-hydroxytryptamine (5-HT) in prostaglandin F(2alpha) (PGF(2alpha))-precontracted pulmonary arteries of weaned pigs. In arterial rings with intact endothelium, the relaxation to 5-HT was biphasic. The high affinity component of relaxation to 5-HT (0.1-10 nM) was abolished by mechanical removal of the endothelium or after the addition of L: -NAME (200 microM), and was inhibited by the 5-HT(2B/2C) receptor antagonist SB 206553 (1 microM), but not the 5-HT(2C) receptor antagonist SB 242084 (0.1 microM). Endothelium-intact arteries were also relaxed by the selective 5-HT(2B) receptor agonist BW 723C86 (pD(2) 7.7). The relaxant response to BW 723C86 was inhibited by 1 microM SB 206553 (pK(B) 6.8). The low affinity component of relaxation to 5-HT (>/=30 nM) remained unaffected after mechanical removal of the endothelium or the addition of L: -NAME. In endothelium-denuded arterial rings, 5-HT, 5-carboxamidotryptamine (5-CT), 5-methoxytryptamine (5-MeOT), and frovatriptan produced monophasic relaxations with pD(2) values of 6.5, 7.5, 5.9, and 4.7 respectively. Relaxant responses to the agonists were antagonized by the selective 5-HT(7) receptor antagonist SB 269970 (pK(B) 8.2-8.9). The relaxant response to the potent 5-HT(7) receptor agonist 5-CT was also antagonized by methiothepin (pK(B) 9.6), pimozide (pK(B) 8.2), mesulergine (pK(B) 7.7), methysergide (pK(B) 7.4), clozapine (pK(B) 7.6), and spiperone (pK(B) 7.4). The estimated pK(B) values argue in favor of an involvement of 5-HT(7) receptors in the direct vasorelaxant action of 5-HT in the pulmonary arteries of weaned pigs. The relaxant response to 5-CT was associated with an increase in cAMP that was surmountably antagonized by SB 269970 (pK(B) 8.6). The present in vitro bioassay can be used to characterize new drugs with potential agonist or antagonist properties at functional 5-HT(7) receptors.
authors.affiliation: Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195 Berlin (Dahlem), Germany.
authors.forename: S
authors.initials: S
authors.lastname: Jähnichen
authors.forename: E
authors.initials: E
authors.lastname: Glusa
authors.forename: H H
authors.initials: HH
authors.lastname: Pertz
mesh_terms: D000465:Algorithms; D000818:Animals; D000242:Cyclic AMP / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology*; D011869:Radioligand Assay; D044403:Receptor, Serotonin, 5-HT2B / Q000187:drug effects / Q000502:physiology*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013552:Swine
chemical_list: D044403:Receptor, Serotonin, 5-HT2B; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C104425:serotonin 7 receptor; D000242:Cyclic AMP
references.citation: Br J Pharmacol. 1999 Oct;128(3):730-4
references.pmid: 10516655
references.citation: Br J Pharmacol. 1998 Jan;123(2):173-82
references.pmid: 9489604
references.citation: J Neurochem. 1996 Jan;66(1):47-56
references.pmid: 8522988
references.citation: J Med Chem. 2000 Feb 10;43(3):342-5
references.pmid: 10669560
references.citation: Trends Pharmacol Sci. 1997 Apr;18(4):104-7
references.pmid: 9149537
references.citation: Pharmacol Rev. 1995 Jun;47(2):255-66
references.pmid: 7568328
references.citation: Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
references.pmid: 13651579
references.citation: Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
references.pmid: 11888546
references.citation: Trends Pharmacol Sci. 1993 Jul;14(7):270-5
references.pmid: 8105597
references.citation: J Med Chem. 1997 Oct 24;40(22):3494-6
references.pmid: 9357513
references.citation: Br J Pharmacol. 1996 Mar;117(5):926-30
references.pmid: 8851512
references.citation: Br J Pharmacol. 1997 Sep;122(1):126-32
references.pmid: 9298538
references.citation: Am J Physiol Heart Circ Physiol. 2000 Mar;278(3):H907-12
references.pmid: 10710360
references.citation: Br J Pharmacol. 1996 Sep;119(2):330-4
references.pmid: 8886417
references.citation: J Cardiovasc Pharmacol. 1998 Aug;32(2):220-4
references.pmid: 9700983
references.citation: FEBS Lett. 1994 Dec 5;355(3):242-6
references.pmid: 7988681
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2001 Jun;363(6):620-32
references.pmid: 11414657
references.citation: Behav Brain Res. 1996;73(1-2):263-8
references.pmid: 8788515
references.citation: J Med Chem. 1995 Jul 7;38(14):2524-30
references.pmid: 7629791
references.citation: Br J Pharmacol. 1998 Sep;125(1):69-78
references.pmid: 9776346
references.citation: Br J Pharmacol. 2000 Jun;130(3):539-48
references.pmid: 10821781
references.citation: J Pharmacol Exp Ther. 1996 Jun;277(3):1560-6
references.pmid: 8667223
references.citation: Br J Pharmacol. 1992 Jul;106(3):703-9
references.pmid: 1504754
references.citation: Neuropsychopharmacology. 2003 Mar;28(3):519-26
references.pmid: 12629531
references.citation: Br J Pharmacol. 2000 May;130(1):79-89
references.pmid: 10781001
references.citation: J Pharmacol Exp Ther. 1990 Jan;252(1):387-95
references.pmid: 2137176
references.citation: Br J Pharmacol. 1999 Jun;127(3):609-16
references.pmid: 10401550
references.citation: Behav Brain Res. 1996;73(1-2):149-52
references.pmid: 8788493
references.citation: Br J Pharmacol. 1996 Jul;118(6):1421-8
references.pmid: 8832067
references.citation: Pharmacol Ther. 1994;62(3):283-324
references.pmid: 7972337
references.citation: Br J Pharmacol. 1995 Jan;114(2):400-4
references.pmid: 7881740
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):471-7
references.pmid: 8391650
references.citation: Eur J Pharmacol. 1990 Aug 21;185(1):123-4
references.pmid: 2226631
references.citation: FEBS Lett. 1995 Aug 21;370(3):215-21
references.pmid: 7656980
references.citation: Mol Cell Biochem. 2002 Sep;238(1-2):81-8
references.pmid: 12349912
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24
references.pmid: 9459568
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Eur J Neurosci. 1996 May;8(5):959-67
references.pmid: 8743744
references.citation: Br J Pharmacol. 1996 Mar;117(6):993-4
references.pmid: 8882587
references.citation: Br J Pharmacol. 2000 Jun;130(3):692-8
references.pmid: 10821800
references.citation: J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10
references.pmid: 7908055
references.citation: Eur J Pharmacol. 2003 Feb 14;461(2-3):207-18
references.pmid: 12586216
references.citation: Headache. 2002 Apr;42 Suppl 2:S47-53
references.pmid: 12028320